Literature DB >> 29496996

Interferon down-regulation of miR-1225-3p as an antiviral mechanism through modulating Grb2-associated binding protein 3 expression.

Min Cheng1, Yuqiang Niu1, Jingjing Fan1, Xiaojing Chi1, Xiuying Liu1, Wei Yang2.   

Abstract

Induction of interferons (IFNs) is a central event of antiviral innate immunity. As crucial posttranscriptional regulators, microRNAs (miRNAs) are important for IFN-mediated host defense. Although screening has indicated a substantial number of miRNAs to be differentially expressed after IFN stimulation, the detailed mechanisms of these miRNAs in the antiviral response are underexplored and of great significance. Here, we show that hsa-miR-1225-3p is specifically down-regulated by type I IFN through the IFN/JAK/STAT signaling pathway. Silencing endogenous miR-1225-3p inhibited infection by multiple IFN-susceptible viruses, including hepatitis C virus, Sendai virus, and Newcastle disease virus. In contrast, overexpression of miR-1225-3p impaired the antiviral effect of IFNs and facilitated viral infection. Regarding the mechanism, we identified growth factor receptor-bound protein 2-associated binding protein 3 (GAB3) as a direct target of miR-1225-3p. GAB3 expression was up-regulated by IFN, and overexpression of GAB3 demonstrated potent antiviral effects through enhancing IFN response and virus-triggered innate immune activation. Taken together, our findings reveal the biological function of miR-1225-3p for the first time and propose a novel antiviral regulation pathway in which miRNA and GAB3 participate. This study contributes to the understanding of host miRNA participation in antiviral processes of IFN.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  GAB3; Growth factor receptor-bound protein 2-associated binding protein 3; host-pathogen interaction; infection; interferon; miR-1225–3p; microRNA (miRNA); virus

Mesh:

Substances:

Year:  2018        PMID: 29496996      PMCID: PMC5912462          DOI: 10.1074/jbc.RA117.000738

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Grb2-associated binding (Gab) proteins in hematopoietic and immune cell biology.

Authors:  Tamisha Y Vaughan; Sheetal Verma; Kevin D Bunting
Journal:  Am J Blood Res       Date:  2011

2.  Scaffolding adaptor protein Gab1 is required for TLR3/4- and RIG-I-mediated production of proinflammatory cytokines and type I IFN in macrophages.

Authors:  Yuejuan Zheng; Huazhang An; Ming Yao; Jin Hou; Yizhi Yu; Gensheng Feng; Xuetao Cao
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

3.  Type I IFN-Inducible Downregulation of MicroRNA-27a Feedback Inhibits Antiviral Innate Response by Upregulating Siglec1/TRIM27.

Authors:  Qingliang Zheng; Jin Hou; Ye Zhou; Yingyun Yang; Xuetao Cao
Journal:  J Immunol       Date:  2015-12-23       Impact factor: 5.422

Review 4.  Type I interferon receptors: biochemistry and biological functions.

Authors:  Nicole A de Weerd; Shamith A Samarajiwa; Paul J Hertzog
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

Review 5.  Aiming for cure in HBV and HDV infection.

Authors:  Jörg Petersen; Alexander J Thompson; Massimo Levrero
Journal:  J Hepatol       Date:  2016-06-03       Impact factor: 25.083

Review 6.  MicroRNAs as regulatory elements in immune system logic.

Authors:  Arnav Mehta; David Baltimore
Journal:  Nat Rev Immunol       Date:  2016-04-28       Impact factor: 53.106

7.  Gab3, a new DOS/Gab family member, facilitates macrophage differentiation.

Authors:  Ingrid Wolf; Brendan J Jenkins; Yan Liu; Martina Seiffert; Joseph M Custodio; Paul Young; Larry R Rohrschneider
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

8.  A long noncoding RNA mediates both activation and repression of immune response genes.

Authors:  Susan Carpenter; Daniel Aiello; Maninjay K Atianand; Emiliano P Ricci; Pallavi Gandhi; Lisa L Hall; Meg Byron; Brian Monks; Meabh Henry-Bezy; Jeanne B Lawrence; Luke A J O'Neill; Melissa J Moore; Daniel R Caffrey; Katherine A Fitzgerald
Journal:  Science       Date:  2013-08-01       Impact factor: 47.728

9.  Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.

Authors:  D M Hotho; J de Bruijne; M Spaan; M A Treitel; A Boonstra; R J de Knegt; H L A Janssen; H W Reesink
Journal:  J Viral Hepat       Date:  2013-01-07       Impact factor: 3.728

10.  Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells.

Authors:  Martina J Schmitt; Demetra Philippidou; Susanne E Reinsbach; Christiane Margue; Anke Wienecke-Baldacchino; Dorothee Nashan; Iris Behrmann; Stephanie Kreis
Journal:  Cell Commun Signal       Date:  2012-12-17       Impact factor: 5.712

View more
  4 in total

1.  microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1.

Authors:  Ruolei Zhong; Sheng Li; Kaifeng Fang; Liu Yang; Li Wang
Journal:  Cell Cycle       Date:  2019-04-24       Impact factor: 4.534

2.  Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.

Authors:  Yu Akazawa; Shoichi Mizuno; Norihiro Fujinami; Toshihiro Suzuki; Yusuke Yoshioka; Takahiro Ochiya; Yasunari Nakamoto; Tetsuya Nakatsura
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

3.  Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5.

Authors:  Weifeng Gong; Xiaobo Guo; Yangmin Zhang
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

4.  circ_SEPT9, a newly identified circular RNA, promotes oral squamous cell carcinoma progression through miR-1225/PKN2 axis.

Authors:  Yilong Ai; Zhe Tang; Chen Zou; Haigang Wei; Siyuan Wu; Dahong Huang
Journal:  J Cell Mol Med       Date:  2020-10-14       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.